Antibody Response Following COVID-19 Vaccination in Malaysian Cancer Patients and Healthy Individuals.

Publication date: Nov 01, 2024

There is a lack of real-world evidence on direct comparisons between COVID-19 vaccines in multiethnic low- and middle-income settings. Cancer patients have an impaired vaccine response due to the disease itself or the effects of treatment. Hence, identifying the best vaccine to use for cancer patients is important. We aimed to compare the antibody response between cancer patients and healthy individuals following COVID-19 vaccination and assess seroconversion rates, vaccine efficacy, and the impact of sex on antibody response, as well as document adverse events in cancer patients. A prospective cohort study of cancer patients and healthy individuals receiving vaccines was conducted in Malaysia. All participants were aged 18 or above at recruitment and received at least two doses of vaccine. We excluded patients who had missing serum antibody data post-first dose and post-second dose. Sociodemographic and clinical data were collected at baseline, prior to vaccination. Data on self-reported breakthrough infection was collected at six months. Multivariable linear mixed-effects regression models were used to investigate the association between the type of vaccine and serum IgG titer. A total of 389 patients with solid (n=276, 71. 0%) or hematologic cancers (n=113, 29. 0%) were included, along with 246 healthy individuals. Most cancer patients received BNT162b2 (n=358, 92. 0%), followed by AZ1222 (n=19, 4. 9%) and Coronavac (n=12, 3. 1%). Most healthy individuals received BNT162b2 (n=151, 61. 4%), followed by Coronavac (n=95, 38. 6%). Vaccination, after adjustment for confounders (pre-vaccine infection, age, ethnicity, comorbidity, timepoint, income, cancer type, and booster), with Coronavac was associated with lower log IgG titer (-3. 09 U/ml, 95% confidence interval=-4. 37 to -1. 80, p

Open Access PDF

Concepts Keywords
Bnt162b2 antibody
Cancers cancer
Healthy cohort study
Timepoint covid-19
Vaccination vaccine

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Cancer
disease MESH seroconversion
disease MESH breakthrough infection
disease MESH infection
disease MESH comorbidity
pathway REACTOME Reproduction
drug DRUGBANK Ademetionine
drug DRUGBANK Coenzyme M

Original Article

(Visited 1 times, 1 visits today)